(Yicai) Nov. 8 -- Edwards Lifesciences will accelerate the introduction of new cardiovascular products into China after the ...

Hospital heart team capacity constraints continued to limit Edwards Lifesciences’ transcatheter aortic valve replacement ...

Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit ...

Edwards Lifesciences Corporation (NYSE ... As the company strives to maintain its dominant position in the Transcatheter Aortic Valve Replacement (TAVR) market while expanding into new territories ...

JenaValve announced today that it received the green light to begin a new randomized controlled trial for its Trilogy device.

New York, New York-- (Newsfile Corp. - November 15, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies, has been navigating a complex landscape of ...

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

( MENAFN - GlobeNewsWire - Nasdaq) Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly ...